Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183777
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Baixin-
dc.contributor.authorGuo, Miaolan-
dc.contributor.authorPeker, Yüksel-
dc.contributor.authorSalord, Neus-
dc.contributor.authorDrager, Luciano F.-
dc.contributor.authorLorenzi-Filho, Geraldo-
dc.contributor.authorTang, Xiangdong-
dc.contributor.authorLi, Yun-
dc.date.accessioned2022-03-04T11:38:27Z-
dc.date.available2022-03-04T11:38:27Z-
dc.date.issued2022-01-25-
dc.identifier.issn2077-0383-
dc.identifier.urihttps://hdl.handle.net/2445/183777-
dc.description.abstractBackground: Obstructive sleep apnea (OSA) is associated with dyslipidemia. However, the effects of continuous positive airway pressure (CPAP) treatment on lipid profiles are unclear. Methods: PubMed/Medline, Embase and Cochrane were searched up to July 2021. Randomized controlled trials (RCTs) of CPAP versus controls with >= 4 weeks treatment and reported pre- and post-intervention lipid profiles were included. Weighted mean difference (WMD) was used to assess the effect size. Meta-regression was used to explore the potential moderators of post-CPAP treatment changes in lipid profiles. Results: A total of 14 RCTs with 1792 subjects were included. CPAP treatment was associated with a significant decrease in total cholesterol compared to controls (WMD = -0.098 mmol/L, 95% CI = -0.169 to -0.027, p = 0.007, I-2 = 0.0%). No significant changes in triglyceride, high-density lipoprotein nor low-density lipoprotein were observed after CPAP treatment (all p > 0.2). Furthermore, meta-regression models showed that age, gender, body mass index, daytime sleepiness, OSA severity, follow-up study duration, CPAP compliance nor patients with cardiometabolic disease did not moderate the effects of CPAP treatment on lipid profiles (all p > 0.05). Conclusions: CPAP treatment decreases total cholesterol at a small magnitude but has no effect on other markers of dyslipidemia in OSA patients. Future studies of CPAP therapy should target combined treatment strategies with lifestyle modifications and/or anti-hyperlipidemic medications in the primary as well as secondary cardiovascular prevention models.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm11030596-
dc.relation.ispartofJournal of Clinical Medicine, 2022, vol 11, num 3-
dc.relation.urihttps://doi.org/10.3390/jcm11030596-
dc.rightscc by (c) Chen, Baixin et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationSíndromes d'apnea del son-
dc.subject.classificationTrastorns del metabolisme dels lípids-
dc.subject.otherSleep apnea syndromes-
dc.subject.otherLipid metabolism disorders-
dc.titleEffect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2022-03-03T11:51:04Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid35160050-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jcm-11-00596-v2.pdf743.08 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons